Human Genome Sciences

Pharma

4 ways to think about GSK’s $3.6B offer for Human Genome Sciences

It has taken a few months and some hand-wringing, but Human Genome Sciences (NASDAQ:HGSI) has agreed to a $3.6 billion offer from GlaxoSmithKline (NYSE:GSK) after a three-month stand-off courtship. It’s yet another example of the deal-making pharmaceuticals are engaged in to keep their drug development pipelines flowing, but there are also a few other ways […]

Pharma

GSK aims to replace entire HGSI board with its own nominees

If you expected the merger and acquisition standoff between GlaxoSmithKline (NYSE:GSK) and Human Genome Sciences (NASDAQ:HGSI) to come to a resolution next week, think again. GSK plans to replace HGS’ entire 12-member board with its own slate of nominees, Reuters reports, citing “sources familiar with the situation.” That process will almost certainly extend beyond the […]

Pharma

GSK starts $2.6B HGSI bid; HGSI will respond in 10 business days

GlaxoSmithKline‘s (NYSE:GSK) forced Human Genome Sciences’ (NASDAQ:HGSI) hand and now the biotechnology company must make a decision about its future on a much faster timetable than it would have liked. GSK today formally commenced its offer to buy HGS at $13 per share, about $2.6 billion, and the British pharmaceuticals giant said shareholders should be […]

Pharma

GSK and HGSI test injectable version of lupus drug Benlysta

GlaxoSmithKline (NYSE:GSK) and drug partner Human Genome Sciences (NASDAQ:HGSI) have started clinical trials on a different version of lupus drug Benlysta that would be easier to administer to patients. Benlysta is currently administered by intravenous infusion. The companies have started a phase 3 clinical trial to test a once-a-week injectable version of the drug. Studies […]

News

GSK’s Benlysta: The new face of a ‘blockbuster’ drug (with more to come)

The lupus drug Benlysta is a perfect example of the new blockbuster drug: expensive products targeting ever more specific segments of the patient population. And as GSK and other pharmaceutical companies continue working on biologics, expect more of this to come. Years before Benlysta’s approval as the first new lupus treatment in more than 50 years, GSK signed a development and commercialization agreement with Human Genome Sciences in which the two companies would share equally in the costs and net proceeds that come from it.

News

Healthcare CEOs earn the biggest bucks (Morning Read)

Healthcare company chief executives took home the biggest paychecks -- a median of $10 million -- of any industry covered by the recent Wall Street Journal CEO Compensation Study, according to the news organization's Health blog. CEOs from Thermo Fisher Scientific, Boston Scientific and Johnson & Johnson were among the top 20 in the list. Unitedhealth Group CEO Stephen Hemsley got the biggest raise last year.